Drug intelligence / Profile preview

QHT025

Development stage: Preclinical
Modality: Vaccines & Immunotherapeutics

Overview

QHT025 is an investigational therapeutic identified using a cell-based microsatellite instability (MSI) reporter platform. It represents a first-in-class agent discovered through this high-throughput screening method designed to detect immune-modulating compounds effective against MSI-high cancers. Limited public data is available, with primary mention in a SITC 2025 abstract highlighting its identification for potential cancer immunotherapy applications, though specific mechanism, developer, and clinical details remain undisclosed.[7]

Beyond the preview

Go deeper on QHT025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QHT025.

Explore the full profile